Cazenove Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Cazenove Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$201K	Buy	+4,496	New	+$195K	0.16%	78

Other funds holding BMY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Cazenove Capital Management's BMY Position: Q2 2013 in Review

Cazenove Capital Management opened a new position in Bristol-Myers Squibb (BMY) in Q2 2013: 4,496 shares worth $201K. The stake represents 0.16% of the portfolio and ranks #78 among its holdings.

1,179 funds tracked by Wall St. Rank hold BMY as of Q2 2013.

Cazenove Capital Management held 4,496 shares of Bristol-Myers Squibb worth $201K as of Q2 2013.
Bristol-Myers Squibb was a new Cazenove Capital Management position in Q2 2013.
Bristol-Myers Squibb made up 0.16% of Cazenove Capital Management's portfolio in Q2 2013, its #78 holding.
1,179 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2013.

Based on Cazenove Capital Management's 13F filing for Q2 2013, filed 14 Aug 2013.